Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $86.36 Consensus Price Target from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $86.3636.

ARWR has been the subject of a number of research reports. Sanford C. Bernstein raised their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $78.00 to $100.00 in a report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Leerink Partners boosted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research note on Wednesday, June 17th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, May 1st. They set an “overweight” rating and a $88.00 price objective on the stock.

Arrowhead Pharmaceuticals Stock Down 0.1%

Shares of Arrowhead Pharmaceuticals stock opened at $79.81 on Friday. Arrowhead Pharmaceuticals has a one year low of $14.30 and a one year high of $84.55. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The stock’s 50-day moving average is $75.19 and its 200 day moving average is $68.14. The firm has a market cap of $11.24 billion, a price-to-earnings ratio of -37.12 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. During the same quarter in the prior year, the company earned $2.75 EPS. The firm’s revenue for the quarter was down 86.4% compared to the same quarter last year. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post -3 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the transaction, the chief financial officer owned 162,905 shares in the company, valued at approximately $11,623,271.75. The trade was a 7.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the sale, the insider directly owned 226,958 shares of the company’s stock, valued at $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,065 shares of company stock valued at $1,912,662 over the last three months. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Tsfg LLC purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. Optiver Holding B.V. raised its position in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares during the last quarter. iSAM Funds UK Ltd purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at $29,000. First Horizon Corp purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $32,000. Finally, WPG Advisers LLC raised its position in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 431 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.